Anglo French Drugs and Industries Unlisted Share Price Today
ISIN INE570E01016.
Anglo-French Drugs & Industries is an Indian pharmaceutical manufacturing company engaged in the production and marketing of pharmaceutical formulations and healthcare products. The company primarily focuses on branded generic medicines across therapeutic segments such as antibiotics, vitamins, gastrointestinal treatments, and other prescription drugs. Founded in 1923, the company has over a century of operating history in the Indian pharmaceutical sector and operates its manufacturing facili…
Anglo French Drugs and Industries
Anglo French Drugs and Industries Unlisted Share Price Today
About Company
Anglo-French Drugs & Industries is an Indian pharmaceutical manufacturing company engaged in the production and marketing of pharmaceutical formulations and healthcare products. The company primarily focuses on branded generic medicines across therapeutic segments such as antibiotics, vitamins, gastrointestinal treatments, and other prescription drugs.
Founded in 1923, the company has over a century of operating history in the Indian pharmaceutical sector and operates its manufacturing facility in Bengaluru, Karnataka. Anglo-French Drugs distributes its products mainly in the domestic market through pharmaceutical distributors and healthcare professionals.
The company operates in the formulations segment, generating revenue primarily from the sale of finished dosage pharmaceutical products. While smaller in scale compared to large pharmaceutical companies, it maintains a diversified product portfolio and continues to operate in India’s highly competitive generic drug market.
Revenue from operations fell from ₹154 Cr in FY21 to ₹90 Cr in FY26, reflecting a shrinking core business base.
The company reported extreme swings in profitability, with exceptionally high margins in FY23 followed by losses in FY24, indicating possible one-off or non-operating income impact.
FY26 saw a sharp rebound with EBITDA rising to ₹28 Cr and PAT to ₹23 Cr, while EPS jumped 226% YoY, indicating improving profitability momentum.
